Amy Hirsh, MD
Allergy · Atlanta, GANPI 1114959319
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Musculoskeletal Transplant Foundation Inc. at 50.7% of the total. Reporting peaked in 2020 at $7,451 and has fallen 84.5% since, to $1,153 in 2025.
Across 295 payments — averaging $46.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Musculoskeletal Transplant Foundation Inc.$7K
- Sanofi$866
- CSL Behring$609
- AstraZeneca$577
- Takeda Pharmaceuticals U.S.A., Inc.$505
- GSK$485
- plus $4K from 26 others
What the payments were for
- Consulting fees$6,97551%
- Speaking & faculty fees$3503%
- Food & beverage$6,36646%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Musculoskeletal Transplant Foundation Inc. | 2 | $6,975 |
| Sanofi | 21 | $866 |
| CSL Behring | 26 | $609 |
| AstraZeneca | 30 | $577 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $505 |
| GSK | 24 | $485 |
| Novartis | 23 | $466 |
| Pharming Healthcare, Inc. | 21 | $444 |
| Biocryst US Sales Co., LLC | 20 | $359 |
| Pfizer | 14 | $350 |
| Regeneron Healthcare Solutions, Inc. | 15 | $341 |
| Amgen | 11 | $259 |
| Grifols USA, LLC | 12 | $244 |
| Optinose US, Inc. | 9 | $220 |
| Octapharma USA, Inc. | 4 | $193 |
| Kaleo, Inc. | 9 | $181 |
| Genentech USA, Inc. | 4 | $102 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Covis Pharma GmbH | 4 | $81 |
| LEO Pharma Inc. | 2 | $47 |
| Bio Products Laboratory USA, Inc. | 4 | $46 |
| Alk-abello, Inc | 2 | $44 |
| Shire North American Group Inc | 2 | $39 |
| Azurity Pharmaceuticals, Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $36 |
| Cycle Pharmaceuticals Inc | 1 | $30 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| Incyte Corporation | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Biocryst Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$350
How this compares
Too few allergy providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $158,874 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $46,582 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $12,722 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,410 |
| Epinephrine | 30 | $4,406 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,119 |
| Azelastine Hcl | 85 | $2,424 |
| Ipratropium Bromide | 34 | $2,021 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $1,804 |
| Fluticasone Propionate | 68 | $1,148 |
| Montelukast Sodium | 92 | $1,085 |
| Azithromycin | 11 | $345 |
| Doxepin Hcl | 14 | $144 |
| Prednisone | 22 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $609 | $158,87426 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $485 | $59,30493 claims |
| AstraZenecaBreztri Aerosphere | $577 | $11,41018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other allergy in Atlanta
- Theodore LeeAtlanta$11K
- Carol WigginsAtlanta$5K
- Umbreen LodiAtlanta$47
- Thomas ChackoAlpharetta$63K
- Donnie DunaganAugusta$19K
- Tricia LeeDecatur$13K
- Anu MongiaCartersville$8K
- Tesneem ChaudharyAugusta$6K
- John HalwigAustell$5K
- Jaya TherattilAugusta$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.